# FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer

> **NCT00323011** · PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 5 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab

## Key facts

- **NCT ID:** NCT00323011
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** drug not available
- **Last updated:** 2014-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323011, "FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00323011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*